Department of Kidney Transplantation, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Institute of Organ Transplantation, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
ACS Biomater Sci Eng. 2024 Sep 9;10(9):5856-5868. doi: 10.1021/acsbiomaterials.4c00844. Epub 2024 Aug 20.
Acute kidney injury (AKI), predominantly associated with the excess production of endogenous ROS, is a serious renal dysfunction syndrome. Ferroptosis characterized by iron-dependent regulated cell death has significant involvement in AKI pathogenesis. As symptomatic treatment of AKI remains clinically limited, a new class of effective therapies has emerged, which is referred to as nanozyme. In our research, a natural mesoporous poly(tannic acid) nanosphere (referred to as PTA) was developed that can successfully mimic the activity of superoxide dismutase (SOD) by Mussel-inspired interface deposition strategy, for effective ROS scavenging and thus inhibition of ferroptosis to attenuate AKI. As anticipated, PTA mitigated oxidative stress and inhibited ferroptosis, as opposed to other modes of cell death such as pyroptosis or necrosis. Furthermore, PTA exhibited favorable biocompatibility and safeguarded the kidney against ferroptosis by enhancing the expression of SLC7a11/glutathione peroxidase 4(GPX4) and Nrf2/HO-1, while reducing the levels of ACSL4 protein in the ischemia and reperfusion injury (IRI)-induced AKI model. Moreover, PTA effectively suppressed aberrant expression of inflammatory factors. Overall, this study introduced antioxidative nanozymes in the form of mesoporous polyphenol nanospheres, showcasing exceptional therapeutic efficacy in addressing ROS-related diseases. This novel approach holds promise for clinical AKI treatment and broadens the scope of biomedical applications for nanozymes.
急性肾损伤(AKI)主要与内源性 ROS 的过度产生有关,是一种严重的肾功能障碍综合征。铁死亡以铁依赖性调节细胞死亡为特征,在 AKI 的发病机制中具有重要作用。由于 AKI 的症状治疗在临床上仍然有限,一种新的有效治疗方法已经出现,被称为纳米酶。在我们的研究中,开发了一种天然介孔聚(单宁酸)纳米球(称为 PTA),它可以通过贻贝类界面沉积策略成功模拟超氧化物歧化酶(SOD)的活性,有效清除 ROS,从而抑制铁死亡,减轻 AKI。正如预期的那样,PTA 减轻了氧化应激并抑制了铁死亡,而不是其他形式的细胞死亡,如细胞焦亡或坏死。此外,PTA 表现出良好的生物相容性,并通过增强 SLC7a11/谷胱甘肽过氧化物酶 4(GPX4)和 Nrf2/HO-1 的表达,同时降低缺血再灌注损伤(IRI)诱导的 AKI 模型中 ACSL4 蛋白的水平,保护肾脏免受铁死亡。此外,PTA 有效抑制了炎症因子的异常表达。总的来说,本研究以介孔多酚纳米球的形式介绍了抗氧化纳米酶,在解决与 ROS 相关的疾病方面展示了出色的治疗效果。这种新方法有望用于临床 AKI 治疗,并拓宽了纳米酶在生物医学应用中的范围。